Comparison of Clinical Efficacy of Finasteride and Dutasteride as 5-alpha Reductase Inhibitor

Abstract

Materials and Methods:From July 2007 to July 2010, 354 benign prostatic hyperplasia patients with combination medication：alpha blocker plus 5-ARI were enrolled. These patients were classified into a finasteride medication group (F group) and dutasteride medication group (D group) retrospectively. We initially measured the total prostate volume (TPV), prostate specific antigen (PSA), International Prostate Symptom Score (IPSS), quality of life score (QoL), maximal flow rate (Qmax), and post-void residual urine (PVR). After at least twelve months of medication, we rechecked these clinical parameters and during medication, side effects related to medication were also recorded. Results:The F group (n=129) and D group (n=225) showed no differences in baseline characteristics for age, TPV, IPSS, QoL scores, or PSA. After medication, decreases in TPV were relatively higher in the D group than the F group (28.2% vs 20.5%). In addition, the decrease in PSA (43.6% vs 39.2%) and IPSS score (4.6 vs 3.5)were also higher in the D group. There were no significant differences in QoL score, Qmax, PVR change, or side effects between the two groups. Conclusions:Dutasteride showed greater efficacy in reduction of TPV and PSA and in symptomatic improvement by IPSS score than finasteride. More large scale studies about the differences on clinical efficacy of finasteride and dutasteride are needed.

The Immunitary role in chronic prostatitis and growth factors as promoter of BPH

“…• Hoon Choi et al, writed that "Dutasteride showed greater ef icacy in reduction of TPV and PSA and in symptomatic improvementby IPSS score than inasteride [5]." See the different chemistry formula and related pharmacolgocial pfro ile of action (reversible or irreversible activity in 5-HT INIBITION) but also related to other factors as tissue penetration.…”

“…These biological indings justify a pharmacological effect of this drug on the in lammatory status of the adenoma. A correlation with clinical improvement was observed [5]. • Skeldon SC et al, "We investigated the risk of cardiovascular events among patients receiving dutasteride relative to inasteride.…”

The Immunitary Role in Cronic Prostatitis and Growth Factors as Promoter of BHP

“…Recently, Latil et al [3] showed thatSerenoa repensinhibits the expression of two" [3] • "Dutasteride showed greater efficacy in reduction of TPV and PSA and in symptomatic improvement by IPSS score than finasteride." [15] (Remember that flogosis can results in partial inefficacy of 5-AR1) FINASTERIDE DUTASTERIDE See the different chemistry formula and related pharmacological profile of action (reversible or irreversible activity in 5-HT INIBITION) but also related to other factors as tissue penetration related chemical groups ad lipophilic balances…”

Untitled

“…Recently, Latil et al [3] showed thatSerenoa repensinhibits the expression of two" [3] • "Dutasteride showed greater efficacy in reduction of TPV and PSA and in symptomatic improvement by IPSS score than finasteride." [15] (Remember that flogosis can results in partial inefficacy of 5-AR1)…”